Ivabradin Heumann

Ivabradine, the active ingredient in Ivabradin Heumann, is a If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradin Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradin Heumann acts on the cardiac If channel to manage conditions where heart‑rate reduction is therapeutic. - Chronic stable angina: decreases the frequency of angina attacks by lowering heart rate without affecting contractility. - Heart failure with reduced ejection fraction: improves symptoms and may reduce hospitalisation by controlling heart rate. - Stable coronary artery disease: provides symptomatic relief of exertional chest pain through heart‑rate modulation.

Ivabradin Heumann may cause a range of adverse reactions.

Common Side Effects: - Bradycardia: heart rate slower than intended. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache. - Dizziness. - Fatigue. - Nausea.

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Symptomatic hypotension. - Persistent visual loss. - Allergic reactions such as rash or angioedema.

Before prescribing Ivabradin Heumann, clinicians should consider several safety measures. - Cardiac monitoring: assess baseline heart rate and rhythm. - Concomitant beta‑blockers: avoid excessive bradycardia by adjusting doses. - Severe hepatic impairment: use with caution, dose may need adjustment. - Pregnancy: safety unknown; avoid unless benefit outweighs risk. - Store at ambient temperature: keep in the original pack, protect from moisture.

Ivabradin Heumann can interact with other medicines that affect heart rate or its metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine plasma levels. - Other heart‑rate‑lowering agents (e.g., digoxin, beta‑blockers): risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ivabradine effectiveness. - Antihypertensives: monitor blood pressure for additive effects. - Antacids containing aluminum or magnesium: may decrease ivabradine absorption if taken simultaneously.